Curing Chronic Myeloid Leukemia

被引：0
作者：
Delphine Rea
Philippe Rousselot
Joelle Guilhot
François Guilhot
François-Xavier Mahon
机构：
[1] Service des Maladies du Sang et EA3518,
[2] Hôpital Saint-Louis,undefined
[3] AP-HP,undefined
[4] Service d’Hématologie et d’Oncologie,undefined
[5] Université de Versailles Saint-Quentin-en-Yvelines,undefined
[6] UFR Paris Ile-de-France Ouest,undefined
[7] Hôpital Mignot,undefined
[8] Inserm CIC 0802,undefined
[9] Université de Poitiers,undefined
[10] CHU de Poitiers,undefined
[11] Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique,undefined
[12] Biothérapies des maladies génétiques et cancers,undefined
[13] INSERM U1035,undefined
[14] Université Bordeaux Ségalen,undefined
来源：
Current Hematologic Malignancy Reports | 2012年 / 7卷
关键词：
BCR-ABL1; Chronic myeloid leukemia; Tyrosine kinase inhibitors; Leukemic stem cells; Cure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress, detection of minimal residual disease precludes therapy termination in most TKI-receiving patients. CML has thus turned into a chronic illness, raising concerns about long-term safety, medication adherence, and health care costs. Although treatment cessation may be feasible in few selected patients achieving deep molecular responses, a definitive cure remains elusive owing to the discovery that TKIs spare quiescent leukemic stem cells (LSC). Understanding mechanisms underlying LSC behavior in TKI-treated patients may provide important clues to develop an array of strategies that ensure the complete destruction of LSC reservoirs and thereby offer CML patients a definitive cure.
引用
收藏
页码：103 / 108
页数：5
相关论文
共 150 条
[1]  
O’Brien SG(1998)Long-term follow-up of the Italian trial of interferon-α versus conventional chemotherapy in chronic myeloid leukemia Blood 92 1541-1548
[2]  
Guilhot F(2003)Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia New Engl J Med 348 994-1004
[3]  
Larson RA(2006)Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials Blood 108 1478-1484
[4]  
Roy L(2009)Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 6041-6051
[5]  
Guilhot J(2008)Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia J Clin Oncol 26 3204-3212
[6]  
Krahnke T(2007)Nilotinib (formerly AMN107), a highly selective BCR-ABL inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 3540-3546
[7]  
Baccarani M(2010)Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia New Eng J Med 362 2260-2270
[8]  
Cortes J(2010)Nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia New Eng J Med 362 2251-2259
[9]  
Pane F(2011)Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation Blood (ASH annual Meeting Abstracts) 118 109-2520
[10]  
Shah NP(2011)Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008 J Clin Oncol 29 2514-7
12345678910